Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing

October 5, 2020

Elicera Therapeutics announced today that it has completed its first share issue and secured 13,2 MSEK in financing to launch unique immuno-oncology company based on groundbreaking research by professor Magnus Essand's research group at Uppsala University. Jamal El-Mosleh is announced as Elicera's CEO.

Download attachment (pdf)
< Back to press releases